Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial
Cancer Chemother Pharmacol. 2019 Dec;84(6):1365.
doi: 10.1007/s00280-019-03964-6.
1 Medical Oncology Department, Hospital Universitario Marqués de Valdecilla and Instituto de Investigación Marqués de Valdecilla (IDIVAL), Avda Valdecilla SN, 39008, Santander, Spain. Fernando.rivera@scsalud.es.
2 Medical Oncology Department, POVISA, Vigo, Spain.
3 Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.
4 Medical Oncology Department, Hospital Arnau de Vilanova, Lleida, Spain.
5 Medical Oncology Department, Hospital Universitario Marqués de Valdecilla and Instituto de Investigación Marqués de Valdecilla (IDIVAL), Avda Valdecilla SN, 39008, Santander, Spain.
6 Medical Oncology Department, Hospital Xeral Cies, Vigo, Spain.
7 Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.
8 Medical Oncology Department, Centro Oncológico de Galicia, Coruña, Spain.
9 Medical Oncology Department, Hospital Gregorio Marañón, Madrid, Spain.
10 Medical Oncology Department, Complejo Hospitalario de A Coruña, Coruña, Spain.
11 Medical Oncology Department, Hospital La Paz, Madrid, Spain.